| Nataliya Lasiychuk, CRNA | |
|
1 Akron General Ave, Akron, OH 44307-2432 | |
| (330) 344-1038 | |
| Not Available |
| Full Name | Nataliya Lasiychuk |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 1 Akron General Ave, Akron, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780235192 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 127360 (Ohio) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 019957 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Akron General Medical Center | Akron, OH | Hospital |
| Mercy Regional Medical Center | Lorain, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Partners Physician Group | 4183529340 | 488 |
| Elyria Anesthesia Incorporated | 7214902170 | 45 |
News Archive
Offering incentives to health care providers who deliver higher quality care and requiring that they comply with national quality standards would help improve patient care, witnesses said at a Senate Finance Committee hearing on Tuesday, CQ HealthBeat reports.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.
The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.
› Verified 5 days ago
| Entity Name | Partners Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841239274 PECOS PAC ID: 4183529340 Enrollment ID: O20031202000183 |
News Archive
Offering incentives to health care providers who deliver higher quality care and requiring that they comply with national quality standards would help improve patient care, witnesses said at a Senate Finance Committee hearing on Tuesday, CQ HealthBeat reports.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.
The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.
› Verified 5 days ago
| Entity Name | Elyria Anesthesia Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710922463 PECOS PAC ID: 7214902170 Enrollment ID: O20040901001554 |
News Archive
Offering incentives to health care providers who deliver higher quality care and requiring that they comply with national quality standards would help improve patient care, witnesses said at a Senate Finance Committee hearing on Tuesday, CQ HealthBeat reports.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.
The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nataliya Lasiychuk, CRNA 16100 Primrose Cir, Middleburg Heights, OH 44130-8478 Ph: () - | Nataliya Lasiychuk, CRNA 1 Akron General Ave, Akron, OH 44307-2432 Ph: (330) 344-1038 |
News Archive
Offering incentives to health care providers who deliver higher quality care and requiring that they comply with national quality standards would help improve patient care, witnesses said at a Senate Finance Committee hearing on Tuesday, CQ HealthBeat reports.
Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.
In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.
The Global Initiative for Chronic Obstructive Lung Disease classification of chronic obstructive pulmonary disease predicts mortality better than the 2011 ABCD scoring system, report Norwegian researchers.
› Verified 5 days ago
Kevin N Brake, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2215 E Waterloo Rd, Ste 313, Akron, OH 44312 Phone: 330-208-2720 Fax: 330-208-2721 | |
Marina Tompkins, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 400 Wabash Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Kevin Wires, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Akron General Ave, Akron, OH 44307 Phone: 330-344-6000 | |
Andrew P Kochan, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-1000 | |
Brian Nash, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 141 N Forge St, Akron, OH 44304 Phone: 330-375-3000 | |
Kristen Waltz, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 525 E Market St, Akron, OH 44304 Phone: 330-375-3765 | |
William C Stanger, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 190 N Union St, Ste 104, Akron, OH 44304 Phone: 330-253-9145 Fax: 330-253-6222 |